Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
stocks
Trump’s US dollar assault is fuelling CBA’s rise
stocks
Insignia Financial: Revised deal still attractive
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,979.40 | 22.00 | -0.24% |
CAC 40 | 7,874.89 | 24.46 | 0.31% |
DAX 40 | 24,465.87 | 225.05 | 0.93% |
Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
FTSE 100 | 9,109.50 | 48.01 | 0.53% |
HKSE | 25,633.29 | 95.22 | 0.37% |
NASDAQ | 21,020.02 | 127.33 | 0.61% |
Nikkei 225 | 41,826.34 | 655.02 | 1.59% |
NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
S&P 500 | 6,358.91 | 49.29 | 0.78% |
S&P/ASX 200 | 8,709.40 | 27.80 | -0.32% |
SSE Composite Index | 3,605.73 | 23.43 | 0.65% |